Allergan loses patent appeal

The U.S. Court of Appeals in Washington finds that two of Allergan''s (AGN) patents covering its eyelash drug Latisse are invalid. The patents cover ways to apply the drug to promote eyelash growth.

Latisse is a variation of the company's glaucoma drug Lumigan. The company developed it after researchers noted that eyelash growth was a side effect of glaucoma treatments.

The court threw out an order preventing Novartis' (NVS) Sandoz, Actavis (ACT) and Apotex from selling generic versions.

Allergan expects Latisse to generate ~$110M is sales this year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs